Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma

Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma

BackgroundWe aimed to characterize serine protease inhibitor Kazal type 1 (SPINK1) as a gene signature for the early diagnosis, molecular targeting, and prediction of immune checkpoint blockade (ICB) treatment response of hepatocellular carcinoma (HCC).MethodsThe transcriptomics, proteomics, and phe...

Full description

Bibliographic Details
Main Authors: Jianlong Jia, Latai Ga, Yang Liu, Zhiyi Yang, Yue Wang, Xuanze Guo, Ruichen Ma, Ruonan Liu, Tianyou Li, Zeyao Tang, Jun Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
serine peptidase inhibitor Kazal type 1 (SPINK1)
immune checkpoint blockade (ICB)
hepatocellular carcinoma (HCC)
tumor immune microenvironment (TIME)
biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.923031/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.923031/full

Similar Items